These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 33036973)

  • 41. Expression of hirudin fusion proteins in mammalian cells: a strategy for prevention of intravascular thrombosis.
    Riesbeck K; Chen D; Kemball-Cook G; McVey JH; George AJ; Tuddenham EG; Dorling A; Lechler RI
    Circulation; 1998 Dec; 98(24):2744-52. PubMed ID: 9851962
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Anticoagulant potential of synthetic and recombinant inhibitors of factor Xa and thrombin in vitro.
    Hauptmann J; Kaiser B
    Blood Coagul Fibrinolysis; 1993 Aug; 4(4):577-82. PubMed ID: 8218854
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacology of hirudin: one hundred years after the first report of the anticoagulant agent in medicinal leeches.
    Markwardt F
    Biomed Biochim Acta; 1985; 44(7-8):1007-13. PubMed ID: 3910034
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hirudin in renal insufficiency.
    Fischer KG
    Semin Thromb Hemost; 2002 Oct; 28(5):467-82. PubMed ID: 12420243
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Construction and in vitro testing of a novel fab-hirudin-based fusion protein that targets fibrin and inhibits thrombin in a factor xa-dependent manner.
    Peter K; Gupta A; Nordt T; Bauer S; Runge MS; Bode C
    J Cardiovasc Pharmacol; 2003 Aug; 42(2):237-44. PubMed ID: 12883328
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clot-targeted micellar formulation improves anticoagulation efficacy of bivalirudin.
    She ZG; Liu X; Kotamraju VR; Ruoslahti E
    ACS Nano; 2014 Oct; 8(10):10139-49. PubMed ID: 25270510
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Determination of prothombinase activation after adding human purified prothrombin to human clot: comparison of hirudin, an activated factor II inhibitor, with DX9065a, an activated factor X inhibitor, on clot-associated thrombin and on prothrombin activation.
    Meddahi S; Bara L; Fessi H; Samama MM
    Blood Coagul Fibrinolysis; 2005 Mar; 16(2):125-33. PubMed ID: 15741800
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The comeback of hirudin--an old-established anticoagulant agent.
    Markwardt F
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):10-23. PubMed ID: 2459000
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hirudin and hirudin analogues as new anticoagulant agents.
    Pineo GF; Hull RD
    Curr Opin Hematol; 1995 Sep; 2(5):380-5. PubMed ID: 9372023
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Higher concentrations of heparin and hirudin are required to inhibit thrombin generation in tissue factor-activated cord plasma than in adult plasma.
    Baier K; Cvirn G; Fritsch P; Köstenberger M; Gallistl S; Leschnik B; Muntean W
    Pediatr Res; 2005 May; 57(5 Pt 1):685-9. PubMed ID: 15718352
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Biological relevance of anti-recombinant hirudin antibodies--results from in vitro and in vivo studies.
    Liebe V; Brückmann M; Fischer KG; Haase KK; Borggrefe M; Huhle G
    Semin Thromb Hemost; 2002 Oct; 28(5):483-90. PubMed ID: 12420244
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pre-clinical and clinical studies on Hirulog: a potent and specific direct thrombin inhibitor.
    Maraganore JM
    Adv Exp Med Biol; 1993; 340():227-36. PubMed ID: 8154339
    [No Abstract]   [Full Text] [Related]  

  • 53. Is the inhibition of both clot-associated thrombin and factor Xa more clinically relevant than either one alone?
    Meddahi S; Samama MM
    Blood Coagul Fibrinolysis; 2009 Apr; 20(3):207-14. PubMed ID: 19657318
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prolonged in vivo anticoagulant activity of a hirudin-albumin fusion protein secreted from Pichia pastoris.
    Sheffield WP; Smith IJ; Syed S; Bhakta V
    Blood Coagul Fibrinolysis; 2001 Sep; 12(6):433-43. PubMed ID: 11555696
    [TBL] [Abstract][Full Text] [Related]  

  • 55. BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis--comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban.
    Finkle CD; St Pierre A; Leblond L; Deschenes I; DiMaio J; Winocour PD
    Thromb Haemost; 1998 Feb; 79(2):431-8. PubMed ID: 9493603
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Local delivery of r-hirudin by a double-balloon perfusion catheter prevents mural thrombosis and minimizes platelet deposition after angioplasty.
    Meyer BJ; Fernández-Ortiz A; Mailhac A; Falk E; Badimon L; Michael AD; Chesebro JH; Fuster V; Badimon JJ
    Circulation; 1994 Nov; 90(5):2474-80. PubMed ID: 7955205
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lepirudin blunts endotoxin-induced coagulation activation.
    Pernerstorfer T; Hollenstein U; Hansen JB; Stohlawetz P; Eichler HG; Handler S; Speiser W; Jilma B
    Blood; 2000 Mar; 95(5):1729-34. PubMed ID: 10688831
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Influence of recombinant hirudin on tissue-factor-induced activation of coagulation in rabbits.
    Kouz J; Czech J; Nicolay U; Dickneite G
    Haemostasis; 1996; 26(4):179-86. PubMed ID: 8872128
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Inhibition of clot-bound and free (fluid-phase thrombin) by a novel synthetic thrombin inhibitor (Ro 46-6240), recombinant hirudin and heparin in human plasma.
    Gast A; Tschopp TB; Schmid G; Hilpert K; Ackermann J
    Blood Coagul Fibrinolysis; 1994 Dec; 5(6):879-87. PubMed ID: 7893925
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inhibition of heparin-resistant microarterial thrombosis by recombinant hirudin: a specific thrombin inhibitor.
    Arnljots B; Bergqvist D
    Plast Reconstr Surg; 1995 Apr; 95(5):894-900. PubMed ID: 7708874
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.